
    
      This a prospective randomized and crossover study for evaluation of pharmacokinetics and
      pharmacodynamics of two epoetins formulations. The subjects will receive in each confinement
      period 4000 IU one of the investigational product subcutaneously, according to randomisation,
      separated by a washout period of 4 weeks. The evaluation of the profile between products
      included serum dosage of medications and reticulocyte count in peripheral blood. Safety
      evaluation data will include report od all adverse events (including type, frequency,
      intensity, seriousness, severity and action taken related to the investigational product
      study).
    
  